| Identification | Back Directory | [Name]
Glesatinib | [CAS]
936694-12-1 | [Synonyms]
Glesatinib
Glesatinib
(MGCD-265
Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]- | [Molecular Formula]
C31H27F2N5O3S2 | [MDL Number]
MFCD30532644 | [MOL File]
936694-12-1.mol | [Molecular Weight]
619.7 |
| Hazard Information | Back Directory | [Description]
Glesatinib is a TKI that targets tumors with MET and AXL alterations. | [Uses]
Glesatinib exhibits anti-tumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance. | [Clinical Use]
Nonclinical models have shown glesatinib to be effective in MET exon 14 skipping mutations. It is currently being evaluated in phase II trials in NSCLC patients with MET alterations. | [in vivo]
Glesatinib (MGCD265; 15 mg/kg/day; orally; 40 weeks) causes a significant decrease in tumor size[1].
| Animal Model: | 4?6-week old female balb/c athymic (nu/nu) mice with HCC827 NSCLC tumor xenografts[1] | | Dosage: | 15 mg/kg | | Administration: |
Orally; daily; 40 weeks | | Result: | Caused a significant decrease in tumor size.
|
|
|
|